HPV Testing with Hybrid Capture 2 (HC2) Technology

HPV testing for sensitive, early detection of cervical cancer risk and disease
The digene HPV Test is the world's most proven human papillomavirus (HPV) test for sensitive, early detection of cervical cancer and disease. The digene HC2 High-Risk HPV DNA Test is for testing for high-risk types of HPV.
The digene HPV Test — preventing cervical cancer
  • Main Image Navi
Worldwide, cervical cancer affects approximately 500,000 women annually and, after breast cancer, is the second-most-common malignancy found in women. The cause of cervical cancer is HPV, and women who have HPV infection can be identified. Cervical cancer is highly preventable and treatable. The "gold standard" in testing for high-risk types of HPV is the digene HPV Test.

The digene HPV Test has been approved in the United States and Canada since 1999. More than 300 peer-reviewed journal articles had data generated with the digene HPV Test, and the test has been studied in clinical trials involving over 1 million women worldwide. More than 90 million tests for carcinogenic HPV have been performed with the digene HPV Test.